Recognizing that fire in the hole is a bona fide issue for Telaprevir-based regimens, VRTX introduced two wrinkles in the phase-3 trial designs to ameliorate this side effect. What are these two wrinkles?
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”